Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.

被引：0

作者：

Moon, Helen H. ^{[1
]}

Kearney, Mairead ^{[2
]}

Mahmoudpour, Seyed Hamidreza ^{[2
]}

Ike, Chiemeka ^{[3
]}

Morris, Valerie A. ^{[3
]}

Rava, Andrew ^{[4
]}

Kim, Sonia ^{[5
]}

Sun, Haiyan ^{[5
]}

Boyd, Marley ^{[5
]}

Rey, Gabriel Gomez ^{[5
]}

机构：

[1] Kaiser Permanente, Riverside, CA USA

[2] Healthcare Business Merck KGaA, Darmstadt, Germany

[3] EMD Serono, Rockland, MA USA

[4] Genesis Res, Hoboken, NJ USA

[5] Genesis Res LLC, Hoboken, NJ USA

来源：

关键词：

283-183-138-12268; 130-544; 261-492-9019; 298-145-222-9001; 261-492-3532-2370-7650-2700; 261-566-9263; 6; 4; 3; 2; 1880; 1876; 3224; 295; 12; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.605

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：605 / 605

页数：1